LP-410 is under clinical development by Lipella Pharmaceuticals and currently in Phase I for Graft Versus Host Disease (GVHD). According to GlobalData, Phase I drugs for Graft Versus Host Disease (GVHD) have an 89% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how LP-410’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

LP-410 overview

LP-410 is under development for the treatment of graft versus host disease. It is administered through oral route.

Lipella Pharmaceuticals overview

Lipella Pharmaceuticals (Lipella Pharma) operates as a clinical-stage biotechnology company that discovers, develops, and commercializes lipid-based therapies. The company provides product LP-10, LP-310. It offers LP-10 product which is a proprietary liposomal formulation of tacrolimus, a potent immunosuppressant that also exhibits anti inflammatory effects. Lipella Pharma offers products for common bladder syndromes such as interstitial cystitis, refractory overactive bladder and hemmorhagic cystitis. The company also provides transmucosal therapy for smooth muscle dysfunction. It also develops new drugs to treat patients with urinary bladder diseases and disorders. The company also conducts clinical trials in different areas. Lipella Pharma is headquartered in Pittsburgh, Pennsylvania, the US.

For a complete picture of LP-410’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 7 February 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.